Clinical stage specialty pharmaceutical company Vascarta Inc announced on Monday that it has obtained the exclusive rights to a novel method of creating more effective cancer therapies with fewer side effects by implementing new and unique linker chemistry developed by the City College of New York (CUNY).
CUNY's novel, patent-pending technology licensed by Vascarta involves linking proven anti-cancer therapeutics such as paclitaxel (Taxol), gemcitabine (Gemzar), doxorubicin (Adriamycin), and methotrexate (Jylamvo) with curcumin. Linking the anti-cancer agents to curcumin optimises the effectiveness of both agents. The linker was designed to undergo breakage once the compound enters a cell.
Dr. Probal Banerjee (inventor of the linker chemistry and professor of Chemistry, Biochemistry, and Neuroscience at CUNY) said: "These new linked molecules are showing greatly increased anti-cancer efficacy, offering the possibility for a new cancer treatment paradigm."
Dr. Joel Friedman, professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and scientific founder & chief scientific officer of Vascarta, added: "Linked curcumin-chemotherapeutic compounds enhances curcumin's bioavailability facilitating more convenient, non-parenteral administration in patients as well as reducing unwanted side effects."
Innate Pharma's IPH4502 to be featured at AACR 2025 Annual Meeting
Rafael Holdings completes merger with Cyclo Therapeutics, focuses on lead asset Trappsol Cyclo
Belay Diagnostics partners with GenomOncology
Privo Technologies launches BeneVet Oncology for animal health
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
Health Canada approves KEYTRUDA for advanced or recurrent endometrial carcinoma
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
Workflow Services completes one-year pilot and expands Colorectal Cancer Screening Education Program
RedHill Biopharma to submit Talicia for UK marketing authorisation